{"meshTagsMajor":["Heterozygote"],"meshTags":["Adolescent","Adult","Aged","Aged, 80 and over","Australia","Case-Control Studies","Cyclin-Dependent Kinase Inhibitor p16","Europe","Female","GTP Phosphohydrolases","Gene Expression Profiling","Heterozygote","Humans","Male","Melanoma","Membrane Proteins","Middle Aged","Mutation","Nevus","Phenotype","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Young Adult"],"meshMinor":["Adolescent","Adult","Aged","Aged, 80 and over","Australia","Case-Control Studies","Cyclin-Dependent Kinase Inhibitor p16","Europe","Female","GTP Phosphohydrolases","Gene Expression Profiling","Humans","Male","Melanoma","Membrane Proteins","Middle Aged","Mutation","Nevus","Phenotype","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Young Adult"],"genes":["CDKN2A"],"publicationTypes":["Letter","Multicenter Study","Research Support, Non-U.S. Gov\u0027t"],"title":"Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.","pubmedId":"24999598"}